Abstract 9961: Combination Therapy with Selective Endothelin Type A Receptor Blockade and Angiotensin-converting Enzyme Blockade Improves Survival of Congestive Heart Failure Similarly to Both Monotherapies: Study in Ren-2 Transgenic Hypertensive Rats with Aorto-Caval Fistula

Petr Kala,Matus Miklovic,Zuzana Honetschlagerova,Petra Skaroupkova,Zuzana Huskova,Vojtech Melenovsky,Josef Veselka,Ludek Cervenka,Petr KalaMatus MiklovicZuzana HonetschlagerovaPetra SkaroupkovaZuzana HuskovaVojtech MelenovskyJosef VeselkaLudek CervenkaUniv Hosp Motol,Prague,Czech RepublicIKEM,Prague,Czech Republic

DOI: https://doi.org/10.1161/circ.144.suppl_1.9961

IF: 37.8

2021-11-10

Circulation

Abstract:Introduction: New therapeutic strategies for congestive heart failure (CHF) are needed, and the current knowledge, including our previous studies, suggests that targeting the endothelin (ET) system could be a promising approach. Hypothesis: Chronic selective blockade of ET type A (ETA) receptors combined with angiotensin-converting enzyme inhibitor (ACEi) would attenuate the course of CHF induced by volume overload achieved by the creation of the aorto-caval fistula (ACF). Methods: ACF was created in Ren-2 transgenic rats (TGR), a model of angiotensin II-dependent hypertension, at the animal age of 8 weeks. Two weeks later the animals were randomly divided into four groups and the therapy began: chronic selective blockade of ETA receptors with atrasentan (ETA block.) (5 mg.kg-1.day-1 in drinking water, n = 31), angiotensin-converting enzyme inhibitor (ACEi) (trandolapril, 2 mg.L-1 in drinking water, n = 32), a combination of atrasentan plus trandolapril (ETA block. + ACEi) ( 5 mg.kg-1.day-1 + 2 mg.L-1 in drinking water, n = 31) or placebo (n = 30). Sham-operated TGR represented a control group (n = 8). The follow-up period was 20 weeks. GraphPad Prism 7 was used for statistical analysis with a log-rank (Mantel-Cox) test to analyze survival data. Results: All sham-operated rats survived till the end of the study. Contrary, all untreated CHF rats died by week 12. The treatment with the ETA block. or with ACEi similarly improved the survival rate, and the final rate was 45 % in ETA block. group (p < 0,01) and 62 % in ACEi group (p < 0,01), the combinational therapy (ETA block. + ACEi) improved survival rate over placebo (52 %, p < 0,01) but not compared with both monotherapies. Conclusions: Our present results suggest that in ACF TGR, the combination treatment with ETA block. and ACEi did not markedly attenuate CHF-dependent mortality over both monotherapies. Thus, more preclinical research needs to be done to deeper understand the endothelin system in CHF.

cardiac & cardiovascular systems,peripheral vascular disease